JP2006321758A - Cosmetic - Google Patents
Cosmetic Download PDFInfo
- Publication number
- JP2006321758A JP2006321758A JP2005147031A JP2005147031A JP2006321758A JP 2006321758 A JP2006321758 A JP 2006321758A JP 2005147031 A JP2005147031 A JP 2005147031A JP 2005147031 A JP2005147031 A JP 2005147031A JP 2006321758 A JP2006321758 A JP 2006321758A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- extract
- skin
- cosmetics
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 60
- 239000000284 extract Substances 0.000 claims abstract description 98
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 20
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 20
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 20
- 229940010454 licorice Drugs 0.000 claims abstract description 20
- 239000010330 ougon Substances 0.000 claims description 28
- 208000010668 atopic eczema Diseases 0.000 abstract description 19
- 201000004624 Dermatitis Diseases 0.000 abstract description 11
- 230000000172 allergic effect Effects 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 7
- 230000007815 allergy Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 4
- 230000035807 sensation Effects 0.000 abstract description 2
- 241000972673 Phellodendron amurense Species 0.000 abstract 3
- 241000207929 Scutellaria Species 0.000 abstract 3
- 206010006784 Burning sensation Diseases 0.000 abstract 1
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000008213 purified water Substances 0.000 description 35
- 239000002453 shampoo Substances 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 29
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 28
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- -1 facial cleansers Substances 0.000 description 25
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 18
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 150000004665 fatty acids Chemical class 0.000 description 18
- 229960005323 phenoxyethanol Drugs 0.000 description 18
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 13
- 241000219051 Fagopyrum Species 0.000 description 13
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 239000000344 soap Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 239000003240 coconut oil Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 235000019482 Palm oil Nutrition 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000001000 micrograph Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000002540 palm oil Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 206010060800 Hot flush Diseases 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000003266 anti-allergic effect Effects 0.000 description 6
- 229960003237 betaine Drugs 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019864 coconut oil Nutrition 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 4
- 208000033830 Hot Flashes Diseases 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- OCKWAZCWKSMKNC-UHFFFAOYSA-N [3-octadecanoyloxy-2,2-bis(octadecanoyloxymethyl)propyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC OCKWAZCWKSMKNC-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 4
- 229960003321 baicalin Drugs 0.000 description 4
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 4
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 4
- 229940075506 behentrimonium chloride Drugs 0.000 description 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 229960004585 etidronic acid Drugs 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940069445 licorice extract Drugs 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 235000021360 Myristic acid Nutrition 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241001237961 Amanita rubescens Species 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- RZCHTMXTKQHYDT-UHFFFAOYSA-N N-Lactoyl ethanolamine Chemical compound CC(O)C(=O)NCCO RZCHTMXTKQHYDT-UHFFFAOYSA-N 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 229940100608 glycol distearate Drugs 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- ONHFWHCMZAJCFB-UHFFFAOYSA-N myristamine oxide Chemical compound CCCCCCCCCCCCCC[N+](C)(C)[O-] ONHFWHCMZAJCFB-UHFFFAOYSA-N 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- XGZOMURMPLSSKQ-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N(CCO)CCO XGZOMURMPLSSKQ-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229940086560 pentaerythrityl tetrastearate Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- RUTSRVMUIGMTHJ-UHFFFAOYSA-M sodium;tetradec-1-ene-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCC=CS([O-])(=O)=O RUTSRVMUIGMTHJ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical class C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- AVBJHQDHVYGQLS-UHFFFAOYSA-N 2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)NC(C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- UWKAYLJWKGQEPM-LBPRGKRZSA-N Linaloyl acetate Natural products CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- AQKOHYMKBUOXEB-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-(16-methylheptadecanoyloxy)oxolan-2-yl]-2-(16-methylheptadecanoyloxy)ethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC(C)C)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCC(C)C AQKOHYMKBUOXEB-RYNSOKOISA-N 0.000 description 1
- OBHAIFOMZXGPIA-DFWYDOINSA-N [Na].CN[C@@H](C)C(O)=O Chemical compound [Na].CN[C@@H](C)C(O)=O OBHAIFOMZXGPIA-DFWYDOINSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- ZZTCCAPMZLDHFM-UHFFFAOYSA-N ammonium thioglycolate Chemical compound [NH4+].[O-]C(=O)CS ZZTCCAPMZLDHFM-UHFFFAOYSA-N 0.000 description 1
- 229940075861 ammonium thioglycolate Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229940096362 cocoamphoacetate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical class C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- ONLRKTIYOMZEJM-UHFFFAOYSA-N n-methylmethanamine oxide Chemical compound C[NH+](C)[O-] ONLRKTIYOMZEJM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940091855 sodium lauraminopropionate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HWCHICTXVOMIIF-UHFFFAOYSA-M sodium;3-(dodecylamino)propanoate Chemical compound [Na+].CCCCCCCCCCCCNCCC([O-])=O HWCHICTXVOMIIF-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は化粧品に関し、詳しくは皮膚の刺激緩和作用、皮膚のアレルギー抑制作用、皮膚の抗炎症作用、抗菌作用を備える化粧品に関する。 The present invention relates to a cosmetic, and more particularly to a cosmetic having a skin irritation reducing action, a skin allergy suppressing action, a skin anti-inflammatory action, and an antibacterial action.
化粧品に対して感受性の強い敏感肌や、感作性の物質に感作されやすいアレルギー肌は、界面活性剤、アルコール類、防腐剤、感触や保湿を向上させる目的で化粧品に用いられるタンパク質類、ビタミン類、ミネラル類その他の水溶性の成分等や界面活性剤で乳化する油性剤等の天然、合成に係わらず、これらの成分の作用により熱感(ほてり感)や湿疹等のアレルギー症状や肌荒れになりやすい。 Sensitive skin that is highly sensitive to cosmetics and allergic skin that is easily sensitized by sensitizing substances, surfactants, alcohols, preservatives, proteins used in cosmetics for the purpose of improving touch and moisture, Regardless of natural or synthetic, such as vitamins, minerals and other water-soluble ingredients, and oil-based agents emulsified with surfactants, these ingredients cause allergic symptoms and rough skin such as hot feeling (hot flashes) and eczema. It is easy to become.
日常生活の身体ケアでシャンプー、洗顔料、せっけんやボディーソープ、頭髪化粧品、スキンケア化粧品等の化粧品は頻繁に使用されるが、これらの化粧品には上記のような成分が含まれので、皮膚の丈夫な健常者にとっては、これらの化粧品は心地よい使用感であっても、敏感肌、アレルギー肌では熱感(ほてり感)や湿疹等のアレルギー症状や肌荒れが発生しやすい。 Cosmetics such as shampoos, facial cleansers, soaps and body soaps, hair cosmetics, skin care cosmetics, etc. are frequently used in daily body care, but these cosmetics contain the above ingredients, so the skin is strong. For those who are healthy, even though these cosmetics are comfortable to use, allergic symptoms such as heat (hot flashes) and eczema are likely to occur on sensitive and allergic skin.
又、せっけん等の洗浄料、洗浄用化粧水、化粧水、パック、リップクリームや口紅、頬紅、アイシャドウ等の化粧料、日焼け止め化粧料、ファンデーション、爪の化粧料、養毛料や整髪料、染毛料、除毛化粧料、ひげそり用化粧料、パーマネント用剤等の皮膚に塗布或いは付着する化粧品にも同様な問題点があった。 Also, soaps, soaps, lotions, lotions, packs, lip balms, lipsticks, blushers, eye shadows, sunscreen cosmetics, foundations, nail cosmetics, hair nourishing and hair stylings, There are similar problems with cosmetics that are applied to or adhered to the skin, such as hair dyes, hair removal cosmetics, shaving cosmetics, and permanent preparations.
このように、アレルギーや炎症を起こした皮膚に対しては、治療用の抗炎症クリームや軟膏を用いてアレルギーや炎症を鎮静化させることが行われている。そして、このような治療薬としてのクリームとしては甘草抽出体及びオウゴン抽出液、或いは更にオウバク抽出液を含有させたアレルギー性皮膚炎用クリーム(特許文献1、2)や、甘草抽出体及びオウバク抽出液を含有させたアレルギー性皮膚炎用クリーム(特許文献3)等が提案されている。 In this way, for allergic and inflamed skin, allergy and inflammation are sedated using a therapeutic anti-inflammatory cream or ointment. And as a cream as such a therapeutic agent, a licorice extract and Ogon extract, or an allergic dermatitis cream (Patent Documents 1 and 2) further containing an Aoba extract, a licorice extract and an Abou extract A cream for allergic dermatitis containing a liquid (Patent Document 3) has been proposed.
しかし、このような治療用クリームはアレルギーや炎症を予防するものではなく、アレルギーや炎症を起こしてしまった皮膚に対して塗布される治療薬であり、その塗布は対症療法的であり、毎日何種類もの化粧品と接触する日常生活において、特に皮膚用洗浄剤や頭髪化粧品等の刺激やアレルギーを考慮していない化粧品に触れる頻度が高い美容師や理容師等においてはこのようなクリームの使用ではアレルギーや炎症を鎮静化させることが困難であった。 However, these treatment creams do not prevent allergies or inflammation, but are treatments applied to the skin that has caused allergies or irritation. In daily life that comes in contact with various types of cosmetics, the use of such creams is particularly important for hairdressers and barbers who frequently touch cosmetics that do not take into account irritation or allergies, such as skin cleaners and hair cosmetics. It was difficult to soothe inflammation and inflammation.
しかし、現代において化粧品はほとんどの人にとって必要不可欠なものとなっている。故に、低刺激であって、熱感(ほてり感)や湿疹等のアレルギー症状や肌荒れを抑制する機能が化粧品に求められていた。 However, cosmetics are indispensable for most people today. Therefore, there is a demand for cosmetics that have low irritation and suppress allergic symptoms such as heat (hot flashes) and eczema and rough skin.
そこで、本願発明は上記課題を解決し、上記のような化粧品を使用しても皮膚からの過剰な脱脂、皮膚のアレルギーや炎症が生じない化粧品、即ち、低刺激であって、熱感(ほてり感)や湿疹等のアレルギー症状や肌荒れを抑制する機能を有する化粧品を提供することを目的とする。 Therefore, the present invention solves the above-mentioned problems, and cosmetics that do not cause excessive defatting from the skin, skin allergies or inflammation even when the above cosmetics are used, that is, low irritation and hot feeling (hot flashes) It is an object of the present invention to provide a cosmetic having a function of suppressing allergic symptoms such as sensation) and eczema and rough skin.
上記課題を解決するための本願発明は、オウゴン抽出物及びオウバク抽出物を含有することを特徴とする化粧品である。 The present invention for solving the above-mentioned problems is a cosmetic product characterized by containing an orange extract and an extract of buckwheat.
又、オウゴン抽出物及び甘草を含有することを特徴とする化粧品である。 Moreover, it is a cosmetic characterized by containing an ougon extract and licorice.
又、オウバク抽出物及び甘草を含有することを特徴とする化粧品である。 Moreover, it is a cosmetic characterized by containing an alum extract and licorice.
又、オウゴン抽出物、オウバク抽出物及び甘草を含有することを特徴とする化粧品である。 Moreover, it is a cosmetic characterized by containing an ougon extract, an alum extract and a licorice.
以上のような本願発明によれば、オウゴン抽出物の抗アレルギー作用及び抗炎症作用とオウバク抽出物の抗菌作用及び抗炎症作用の相乗効果により、使用しても皮膚からの過剰な脱脂、皮膚のアレルギーや炎症が生じない化粧品、即ち、低刺激であって、熱感(ほてり感)や湿疹等のアレルギー症状や肌荒れを抑制する機能を有する化粧品を提供することが可能となった。 According to the present invention as described above, due to the synergistic effect of the antiallergic action and anti-inflammatory action of the extract of buckwheat and the antibacterial action and anti-inflammatory action of the extract of buckwheat, excessive defatting from the skin even when used, It has become possible to provide a cosmetic product that does not cause allergies or inflammation, that is, a cosmetic product that has low irritation and has a function of suppressing allergic symptoms such as heat feeling (hot flush) and eczema and rough skin.
又、オウゴン抽出物及び/又はオウバク抽出物に甘草を加えることにより、甘草の保湿作用及び抗アレルギー作用が上記のようなオウゴン抽出物及び/又はオウバク抽出物の作用と相乗効果をもたらし、より使用しても皮膚からの過剰な脱脂、皮膚のアレルギーや炎症が生じない化粧品、即ち、より低刺激であって、熱感(ほてり感)や湿疹等のアレルギー症状や肌荒れを抑制する機能を有する化粧品を提供することが可能となった。 Moreover, by adding licorice to the extract of Augon and / or Oat extract, the moisturizing action and anti-allergic action of licorice bring about the synergistic effect with the action of Ougon extract and / or Oat extract as described above, and more use Cosmetics that do not cause excessive defatting from the skin, skin allergies or irritation, that is, cosmetics that are less irritating and have the ability to suppress allergic symptoms such as heat (hot flush) and eczema and rough skin It became possible to provide.
以下本発明の実施の形態を詳細に説明する。本発明の化粧品はオウゴン抽出物、オウバク抽出物及び甘草を含有する。 Hereinafter, embodiments of the present invention will be described in detail. The cosmetic of the present invention contains ougon extract, agaric extract and licorice.
尚、本出願でいう化粧品は薬事法にいう医薬品は除外されるが、薬事法にいう化粧品に限定されず、医薬部外品をも含み、皮膚に使用する化粧品、毛髪に使用する化粧品、歯磨、浴用剤、芳香品等が含まれ、皮膚に使用する化粧品としては、せっけん、合成化粧せっけん、液状ボディ洗浄料(ボディーソープ)、洗顔料等の洗浄料、クレンジングクリーム、洗浄用化粧水、化粧水、乳液、美容液、ローション、液状パック、ペースト状パック等のパック、粉白粉、水白粉、練白粉等の白粉、打粉、ファンデーション、口紅、頬紅等の化粧品、マニュキュア、ネイルエナメル、エナメルリムーバー等の爪の化粧料、アイライナー、アイシャドウ等の目のまわりの化粧料、日焼け止め化粧料、サンタン化粧料等が挙げられ、毛髪に使用する化粧品としては、シャンプー、リンス、トリートメント、更にはヘアトニック、ヘアコンディショナー、ヘアオイル、ヘアリキッド、ヘアムース、ヘアジェル等の養毛料や整髪料(ヘアセット剤)、パーマネントウェーブ用剤、染毛料等の頭髪化粧品、除毛化粧料等の化粧料、或いはシェービングローション、アフターシェービングローション等のひげそり用化粧料等が挙げられる。 The cosmetics referred to in this application exclude the pharmaceuticals referred to in the Pharmaceutical Affairs Law, but are not limited to the cosmetics referred to in the Pharmaceutical Affairs Law, including quasi-drugs, cosmetics used on the skin, cosmetics used on the hair, and toothpaste. Cosmetics to be used on the skin include soap, synthetic soap, liquid body cleanser (body soap), cleanser such as facial cleanser, cleansing cream, cleansing lotion, makeup Cosmetics such as water, milky lotion, cosmetic liquid, lotion, liquid pack, paste-like pack, white powder such as powdered white powder, water white powder, whitened powder, powdered powder, foundation, lipstick, blusher, manicure, nail enamel, enamel remover, etc. Cosmetics used on the hair, such as nail cosmetics, eyeliner, eye shadow cosmetics, sunscreen cosmetics, suntan cosmetics, etc. Hair shampoos, rinses, treatments, hair tonics, hair conditioners, hair oils, hair liquids, hair mousses, hair gels and other hair nourishing and hair styling products (permanent wave preparations, hair dyes, etc.) And cosmetics such as hair removal cosmetics, and shaving cosmetics such as shaving lotions and after shaving lotions.
漢方におけるオウゴンの作用は「炎症を去り、水毒を除き、清涼解熱と利尿の効がある」とされている。オウゴンの一般薬理作用については緩下作用、利尿作用があることは確認されている。又、オウゴンの成分がフラボノイドであるところから所謂ビタミンP様活性として抗炎症作用が調べられ、アスピリンに匹敵する効果が認められている。更に、オウゴンの抗アレルギー作用について、感作したモルモットの摘出回腸でSchultz−Dale反応をみると強い抑制効果が認められている。 The action of ougon in Chinese medicine is said to “remove inflammation, remove water poisoning, and have a refreshing fever and diuretic effect”. It has been confirmed that the general pharmacological action of ougon has a laxative action and a diuretic action. Further, since the component of ougon is a flavonoid, its anti-inflammatory action has been examined as a so-called vitamin P-like activity, and an effect comparable to aspirin has been recognized. Furthermore, regarding the antiallergic action of hornon, when a Schultz-Dale reaction is observed in the isolated ileum of sensitized guinea pigs, a strong inhibitory effect is recognized.
オウゴンは主成分のフラボノイドはbaicalin4.3%、baicalein、wogonin0.5%、wogonin glucuronide、orxylinA、この他ステロイド、糖類が存在するオウゴンの抗アレルギー作用の有効成分はbaicalinであり、そのgluconのbaicaleinはモル比でbaicalinと同程度のmediator遊離抑制作用を示したので活性構造はbaiclein部分にある。baicleinはanaphylexis型反応を抑制するのみならず、reaginによって惹起されるアトピー型の反応をも抑制する。 Ougon is the main component of flavonoids: baicalin 4.3%, baicalein, wogolin 0.5%, wogolin glucoronide, orxylin A, and other steroids and saccharides that have anti-allergic activity are baicalin. Since the mediator release inhibitory action was similar to baicalin in molar ratio, the active structure is in the bailelein part. baiclein not only suppresses the anaphylaxis type reaction but also suppresses the atopy type reaction induced by reagin.
又、アトピー型抑制剤であるrisodium cromoglycate(DSCG)はbaicaleinと共通のchromono骨格を持つが、DSCGはreaginによる反応しか押さえられないのに対しbaicaleinはnon−reaginによる反応をも押さえることが出来る。以上のことからbaicaleinがアレルギー反応の発現の機序のうち従来の薬物では及ばない作用点に作用することが解かる。又、オウゴンは赤痢菌、チフス菌、緑膿菌、ブドウ球菌、溶血性レンサ球菌等に対し、抗菌作用があるとする主張がある。 In addition, the atopic inhibitor risodium chromicate (DSCG) has a common chromo skeleton with baicalalein, whereas DSCG can suppress only the reaction by regin, whereas baicalalein can also suppress the reaction by non-reagin. From the above, it can be understood that baicalalein acts on the action point that is not achieved by conventional drugs among the mechanisms of the development of allergic reactions. In addition, it is claimed that ougon has antibacterial action against Shigella, Salmonella typhi, Pseudomonas aeruginosa, staphylococci, hemolytic streptococci and the like.
本発明で使用するオウゴン抽出物は特に限定されないが、例えばエタノール、1.3−ブチレングリコール又は水等で抽出したオウゴンエキス等を用いることが出来る。そして、エタノールによる抽出物の一例としてはbaicalin0.15〜0.25w/v%含むもの等が挙げられる。本発明ではこのオウゴン抽出物を化粧品中0.01重量%以上含有させる。特に0.01〜10重量%が好ましい。0.01重量%以下であると充分な効果が生じない場合があるからである。一方オウゴン抽出物を含有させることで発生する副作用、例えば洗浄剤に於いて泡立ちが悪い等はないので、含有量の上限は特にない。 The hornon extract used in the present invention is not particularly limited, and for example, hornon extract extracted with ethanol, 1.3-butylene glycol, water or the like can be used. And as an example of the extract by ethanol, what contains baicalin 0.15-0.25 w / v% etc. are mentioned. In the present invention, this ougon extract is contained in the cosmetic in an amount of 0.01% by weight or more. Particularly preferred is 0.01 to 10% by weight. This is because if the amount is 0.01% by weight or less, sufficient effects may not occur. On the other hand, there is no particular upper limit of the content because there is no side effect caused by the inclusion of ougon extract, for example, the foaming is not bad in the cleaning agent.
オウバクは、オウレン、オウゴンと共にベルベリンを主成分とする生薬であるが、漢方に於ける用法はオウレン、オウゴンと異なる場合が多い。オウバクについては消化器作用、眼疾患など殺菌作用を推測させる用法が多い。又、オウバクの薬効には外用剤としての用法に特徴があり、ベルベリンは外用殺菌剤として単なる殺菌作用では説明出来ない創面治療促進作用があると報告されている。 Oubak is a herbal medicine that contains berberine as a main component together with ouren and ougon, but its usage in Kampo is often different from ouren and ougon. There are many uses for the agaric that make it possible to infer the bactericidal action such as digestive action and eye diseases. In addition, it is reported that the medicinal effect of Aoba is characterized by its use as an external preparation, and berberine has an effect of promoting wound treatment that cannot be explained by a simple bactericidal action as an external bactericidal agent.
このようにオウバクは殺菌作用を有するが、ブドウ球菌に対し5%で発育阻止作用を認められ、肺炎菌には最も強い抗菌力を示し、ベルベリン0.625%、オウバク末は0.015%の濃度まで阻止作用を示した。 As described above, the buckwheat has a bactericidal action, but has a growth inhibitory action against staphylococci at 5%, exhibits the strongest antibacterial activity against pneumococci, with berberine 0.625%, and the powdered apricot powder 0.015%. Inhibiting action up to the concentration.
又オウバクの薬効には単なる殺菌作用の強さでは説明できない創面治癒作用があるが、例えばウサギは背部皮膚に作成した筋肉に達した2cm2の新鮮創傷の治癒はアクリノールに比べてベルベリン溶液処理群が明らかに早かった。試験管での殺菌効力は明らかに合成殺菌剤に比し弱いので、収斂性の抗炎症作用が治癒の促進に関与しているものと思われる。又オウバクのアルカロイド以外の成分としてリノール酸、パルミチン酸とフィトステリンのエステルが同定されている。 In addition, the medicinal effect of Aoba has a wound healing action that cannot be explained by the strength of mere bactericidal action. For example, rabbits are able to heal 2 cm 2 fresh wounds that have reached the muscles created on the back skin, compared with acrinol. Was obviously early. Since the bactericidal efficacy in test tubes is clearly weaker than that of synthetic fungicides, it seems that astringent anti-inflammatory action is involved in promoting healing. In addition, linoleic acid, esters of palmitic acid and phytosterin have been identified as components other than alba alkaloids.
古来オウバク末は火傷、湯ただれに用いられ、近年では受精卵を用いた抗炎症作用のスクリーニング研究に於いて強い抗炎症作用が検出されている。即ち、受精鶏卵の胚に検体を浸漬した濾紙のディスクを作用させ肉芽形成を阻害する作用を指標として活性を調べたところ、オウバクの50%メタノール抽出粗エキスは500μg/diseの用量で53%の肉芽阻止作用を示した。塩酸ベルベリンは50μg/diseの用量で68.8%の抑制を示した。オウバクの炎症に関与する成分は明確でない。 Traditionally, Aoba powder has been used for burns and baths, and in recent years, strong anti-inflammatory activity has been detected in screening studies of anti-inflammatory activity using fertilized eggs. That is, when the activity was examined using a filter paper disk in which the specimen was immersed in the embryo of a fertilized chicken egg to inhibit granulation formation as an index, the 50% methanol extracted crude extract of oak was 53% at a dose of 500 μg / dise. It showed granulation inhibitory action. Berberine hydrochloride showed 68.8% inhibition at a dose of 50 μg / dise. Ingredients involved in the inflammation of oak are not clear.
本発明で使用するオウバク抽出物は特に限定されないが、例えばエタノール、1.3−ブチレングリコール又は水等で抽出したオウバクエキス等を用いることが出来る。そして、1.3ブチレングリコールによる抽出物の一例としては、ベルベリンを塩化ベルべリンとして0.15〜0.25w/v%含むもの等が挙げられる。本発明ではこのオウバク抽出物を化粧品中0.01重量%以上含有させる。特に0.01〜10重量%が好ましい。0.01重量%以下であると充分な効果が生じない場合があるからである。一方オウバク抽出物を含有させることで発生する副作用、例えば洗浄剤に於いて泡立ちが悪い等はないので、含有量の上限は特にない。 Although the buckwheat extract used by this invention is not specifically limited, For example, the buckwheat extract extracted with ethanol, 1.3-butylene glycol, water, etc. can be used. And as an example of the extract by 1.3 butylene glycol, what contains 0.15-0.25 w / v% of berberine as berberine chloride is mentioned. In the present invention, the alum extract is contained in the cosmetic in an amount of 0.01% by weight or more. Particularly preferred is 0.01 to 10% by weight. This is because if the amount is 0.01% by weight or less, sufficient effects may not occur. On the other hand, there is no particular upper limit on the content because there is no side effect caused by the inclusion of the extract of a buckwheat, for example, there is no bad foaming in the detergent.
甘草は古くから消炎効果がある薬草として知られており、その有効成分であるグリチルリチン酸類は抗炎症、抗アレルギー、抗消化性潰瘍作用などのため、急性、慢性の皮膚炎の他、アフタ性口内炎などに効果があるとして基礎化粧品や歯磨中に添加されているものがある。又、保湿作用をも備えている。本発明で使用する甘草は特に限定されず、甘草末や甘草抽出物を用いることが出来る。 Licorice has long been known as an anti-inflammatory medicinal herb, and its active ingredient, glycyrrhizic acid, has anti-inflammatory, anti-allergic, anti-peptic ulcer effects, etc. Some have been added to basic cosmetics and dentifrices as effective. It also has a moisturizing action. The licorice used in the present invention is not particularly limited, and licorice powder and licorice extract can be used.
甘草抽出物であるが、glycyrrhizinやそのゲニンのglycyrrhetic acidは副腎皮質の水電解質や糖質ホルモン様作用、エストロゲン作用、鎮咳作用、抗炎症作用、抗アレルギー作用など数多くの薬理効果がある。甘草には多数のグリチルリチン酸が含まれるが、グリチルリチン酸モノアカモニウム及びカリウムは熱水には溶けるが、放冷するとゲル状になり、冷水には溶けにくい。P−グリチルリチン酸はピリジンに溶けやすく、水には殆ど溶けない等水に溶けないものが多い中でグリチルリチン酸ジカリウムは常温で水に85%溶解するので使用し易い。 Although it is a licorice extract, glycyrrhizin and its glycyrrhetic acid have many pharmacological effects such as a water electrolyte of the adrenal cortex, a carbohydrate hormone-like action, an estrogen action, an antitussive action, an anti-inflammatory action, and an antiallergic action. Licorice contains a large number of glycyrrhizic acids, but monoacamonium glycyrrhizinate and potassium are soluble in hot water, but are gelled when allowed to cool and are hardly soluble in cold water. P-glycyrrhizic acid is easily soluble in pyridine, and in many cases it is insoluble in water such as insoluble in water. Dipotassium glycyrrhizinate is easily used because it dissolves 85% in water at room temperature.
グリチルリチン酸ジカリウムを用いる場合には化粧品中0.01重量%以上含有させる。0.01重量%以下であると充分に効果が生じない場合があるからである。特に0.01から10重量%が好ましく、更には0.1〜2重量%がより好ましい。 When dipotassium glycyrrhizinate is used, it is contained in the cosmetic in an amount of 0.01% by weight or more. This is because if the amount is 0.01% by weight or less, sufficient effects may not be obtained. In particular, it is preferably 0.01 to 10% by weight, and more preferably 0.1 to 2% by weight.
又、オウゴン抽出物、オウバク抽出物及び甘草を含有するのではなく、これらのうち何れか二種を含有させて、即ち、オウゴン抽出物及びオウバク抽出物を含有させ、又はオウゴン抽出物及び甘草を含有させ、或いはオウバク抽出物及び甘草を含有させて化粧品を調製することとしてもよい。 In addition, it does not contain ougon extract, oak extract and licorice, but contains any two of them, that is, ougon extract and oak extract, or ougon extract and licorice. It is good also as preparing cosmetics by making it contain or containing an alum extract and a licorice.
本発明の化粧品は上記の成分の他、その化粧品の特性、目的、剤型等に従って、夫々の化粧品に通常用いられる成分を本発明の目的、作用、効果を損なわない範囲で適宜選択して添加して使用する。他の成分としては例えば界面活性剤、油分、保湿剤、柔軟剤、感触向上剤、油性剤、乳化剤、酸化防止剤、防腐剤、防黴剤、エモリエント剤、pH調整剤、キレート剤、安定化剤、紫外線吸収剤、アルコール類、シリコン化合物、増粘剤、粘度調整剤、可溶化剤、パール化剤、香料、清涼剤、殺菌剤、抗菌剤、天然抽出物、着色剤、褪色防止剤、精製水その他の溶剤、噴射剤等が挙げられ、これらの成分を一種類単独で用いてもよく、二種類以上を組合わせて適宜添加可能である。 In addition to the above-mentioned components, the cosmetics of the present invention are appropriately selected and added according to the properties, purposes, dosage forms, etc. of the cosmetics within a range that does not impair the purposes, functions, and effects of the present invention. And use it. Other components include, for example, surfactants, oils, moisturizers, softeners, feel improvers, oiliness agents, emulsifiers, antioxidants, antiseptics, antifungal agents, emollients, pH adjusters, chelating agents, stabilization Agents, ultraviolet absorbers, alcohols, silicon compounds, thickeners, viscosity modifiers, solubilizers, pearlizing agents, fragrances, fresheners, bactericides, antibacterial agents, natural extracts, colorants, anti-fading agents, Examples include purified water and other solvents, propellants, and the like. These components may be used alone or in combination of two or more.
又、これらの各種成分を用いて適宜液状、ローション、スプレータイプ、ジェル、ワックス、クリーム等の形態に調製して使用することが出来る。又、本発明の化粧品の製造方法、上記の添加成分の添加方法、配合量には特に限定がなく、公知の方法、配合量を採用することも出来る。 Further, these various components can be appropriately used in the form of liquid, lotion, spray type, gel, wax, cream and the like. Moreover, there is no limitation in particular in the manufacturing method of the cosmetics of this invention, the addition method of said addition component, and compounding quantity, A well-known method and compounding quantity can also be employ | adopted.
以下に本発明の実施例をあげて本発明について更に詳細に説明するが、本発明がこれら実施例にのみ限定されるものではない。 EXAMPLES The present invention will be described in more detail below with reference to examples of the present invention, but the present invention is not limited to these examples.
下記に示す配合のシャンプー剤を調製した。
テトラステアリン酸PEG−150ペンタエリスリチル 1.5重量%
N−ラウロイル−L−グルタミン酸トリエタノールアミン 25.0重量%
ココアンホ酢酸ナトリウム 7.0重量%
グリセリン 2.0重量%
フェノキシエタノール 0.3重量%
EDTA−2Na 0.5重量%
塩化ナトリウム 0.5重量%
オウゴンエキス 2.0重量%
オウバクエキス 2.0重量%
グリチルリチン酸ジカリウム 0.1重量%
精製水 残部
A shampoo agent having the composition shown below was prepared.
PEG-150 pentaerythrityl tetrastearate 1.5% by weight
N-lauroyl-L-glutamic acid triethanolamine 25.0% by weight
Sodium cocoamphoacetate 7.0% by weight
Glycerin 2.0% by weight
Phenoxyethanol 0.3% by weight
EDTA-2Na 0.5% by weight
Sodium chloride 0.5% by weight
Ougon extract 2.0% by weight
Oat extract 2.0% by weight
Dipotassium glycyrrhizinate 0.1% by weight
Purified water balance
調製方法としては、精製水を80℃に加熱し、攪拌しながらテトラステアリン酸PEG−150ペンタエリスリチル、N−ラウロイル−L−グルタミン酸トリエタノールアミン、ココアンホ酢酸ナトリウム、グリセリン、フェノキシエタノール、EDTA−2Na及び塩化ナトリウムを順次投入して均一になるまで攪拌しながら50℃まで冷却する。更に攪拌しながらオウゴンエキス、オウバクエキス及びグリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, purified water was heated to 80 ° C. and stirred with PEG-150 pentaerythrityl tetrastearate, N-lauroyl-L-glutamate triethanolamine, cocoamphoacetate sodium, glycerin, phenoxyethanol, EDTA-2Na and Sodium chloride is sequentially added and cooled to 50 ° C. with stirring until uniform. Further, agron extract, agaric extract and dipotassium glycyrrhizinate are sequentially added with stirring, and the mixture is stirred until uniform.
へアレスマウスの背部に上記実施例1の本発明のシャンプーとオウゴン抽出物、オウバク抽出物及び甘草を含有しない市販のシャンプーA、B及びCの三種、合計四種のシャンプーを一匹毎に一日1回、連続して1週間塗布して皮膚の変化を観察した。市販のシャンプーA、B及びCでは連続塗布二日目からマウスの皮膚に症状が発症した。 The shampoo of the present invention of Example 1 above, the extract of Augon, the extract of Aoba and the commercially available shampoos A, B and C containing no licorice, four kinds of shampoos in total, one for each hairless mouse. The skin change was observed once a day and continuously for 1 week. With commercially available shampoos A, B and C, symptoms developed on the skin of the mice from the second day of continuous application.
図1は1週間経過後のへアレスマウスの背部の写真で、1は本発明のシャンプーを用いたもの、2から4は夫々市販のシャンプーA、B、Cを用いたものである。図2はコントロールとしてシャンプー塗布前の正常な皮膚断面の顕微鏡写真、図3から5は1週間経過後の皮膚断面の顕微鏡写真であり、図3は本発明のシャンプーを用いた図1の1のマウスのもの、図4はシャンプーAを用いた図1の2のマウスのもの、図5はシャンプーBを用いた図1の3のマウスのものである。又、図6はシャンプーBを用いた図1の3のマウスの肝臓断面の顕微鏡写真である。 FIG. 1 is a photograph of the back of a hairless mouse after the lapse of 1 week, 1 using the shampoo of the present invention, and 2 to 4 using commercially available shampoos A, B, and C, respectively. FIG. 2 is a micrograph of a normal skin cross section before shampoo application as a control, FIGS. 3 to 5 are micrographs of the skin cross section after one week, and FIG. 3 is a diagram of 1 in FIG. 1 using the shampoo of the present invention. FIG. 4 shows the mouse of FIG. 1 using shampoo A, and FIG. 5 shows the mouse of FIG. 1 using shampoo B. FIG. 6 is a photomicrograph of the liver cross section of the mouse of FIG.
市販のシャンプーA、B、Cを用いたものは病変の程度は夫々異なるが、症状が発症した。シャンプーAを用いた図1の2及び図4のマウスは肌荒れによる表皮特に角質の肥厚がみられる。シャンプーBを用いた図1の3、図5及び図6のマウスの例では皮膚に潰瘍が見られ、体重の減少や肝臓及び腎臓に炎症が起こる等の内蔵病変も見られる。市販のシャンプーCを用いたものは軽度の症状がみられた。それに対し、本発明のシャンプーを塗布したマウスには、図1の1及び図3にみられるように、図2に示すコントロールと同様の状態が示され塗布前と何等変化が見られなかった。 Symptoms developed with commercial shampoos A, B, and C, although the degree of lesion was different. 1 and 4 using shampoo A show thickening of the epidermis, especially keratin, due to rough skin. In the example of the mouse of FIG. 1, 3, 5 and 6 using shampoo B, ulcers are seen in the skin, and internal lesions such as weight loss and inflammation in the liver and kidneys are also seen. A mild symptom was observed when the commercially available shampoo C was used. In contrast, as shown in FIGS. 1 and 3, the mice to which the shampoo of the present invention was applied showed the same state as the control shown in FIG. 2, and no change was seen before application.
下記に示す配合のシャンプー剤を調製した。
カチオン化セルロース 0.5重量%
ジステアリン酸PEG−150 1.5重量%
テトラデセンスルホン酸ナトリウム 15.0重量%
ヤシ油脂肪酸アミドプロピルジメチルベタイン 15.0重量%
エチドロン酸 0.3重量%
フェノキシエタノール 0.5重量%
グリセリン 3.0重量%
オウゴンエキス 1.0重量%
オウバクエキス 1.0重量%
精製水 残部
A shampoo agent having the composition shown below was prepared.
Cationized cellulose 0.5% by weight
PEG-150 distearate 1.5% by weight
Sodium tetradecenesulfonate 15.0% by weight
Coconut oil fatty acid amidopropyldimethylbetaine 15.0% by weight
Etidronic acid 0.3% by weight
Phenoxyethanol 0.5% by weight
Glycerin 3.0% by weight
Ogon Extract 1.0% by weight
Oat extract 1.0% by weight
Purified water balance
調製方法としては、カチオン化セルロース、ジステアリン酸PEG−150及び精製水を80℃に加熱し、攪拌しながらテトラデセンスルホン酸ナトリウム、ヤシ油脂肪酸アミドプロピルジメチルベタイン、エチドロン酸及びフェノキシエタノールを順次投入して均一になるまで攪拌しながら50℃まで冷却する。更に攪拌しながらグリセリン、オウゴンエキス、オウバクエキスを順次投入して均一になるまで攪拌して完成する。 As a preparation method, cationized cellulose, PEG-150 distearate and purified water were heated to 80 ° C., and sodium tetradecenesulfonate, coconut oil fatty acid amidopropyldimethylbetaine, etidronic acid and phenoxyethanol were sequentially added while stirring. Cool to 50 ° C. with stirring until uniform. Further, glycerin, ougon extract, and buckwheat extract are sequentially added while stirring, and the mixture is stirred until uniform.
下記に示す配合のシャンプー剤を調製した。
ポリオキシエチレンスルホコハク酸ラウリルニナトリウム 20.0重量%
N−ヤシ油脂肪酸アシルグリシンナトリウム 10.0重量%
ラウラミノプロピオン酸ナトリウム 5.0重量%
1,3−ブチレングリコール 3.0重量%
フェノキシエタノール 0.5重量%
EDTA−2Na 0.5重量%
クエン酸 0.2重量%
オウゴンエキス 0.2重量%
グリチルリチン酸ジカリウム 0.8重量%
精製水 残部
A shampoo agent having the composition shown below was prepared.
Polyoxyethylene sulfosuccinate lauryl disodium 20.0% by weight
N-coconut oil fatty acid acylglycine sodium 10.0% by weight
Sodium Lauraminopropionate 5.0% by weight
1,3-butylene glycol 3.0% by weight
Phenoxyethanol 0.5% by weight
EDTA-2Na 0.5% by weight
Citric acid 0.2% by weight
Ougon extract 0.2% by weight
Dipotassium glycyrrhizinate 0.8% by weight
Purified water balance
調製方法としては、精製水を80℃に加熱し、攪拌しながらポリオキシエチレンスルホコハク酸ラウリルニナトリウム、N−ヤシ油脂肪酸アシルグリシンナトリウム、ラウラミノプロピオン酸ナトリウム、1,3−ブチレングリコール、フェノキシエタノール、EDTA−2Na及びクエン酸を順次投入して均一になるまで攪拌しながら50℃まで冷却する。更に攪拌しながらオウゴンエキス、グリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, purified water is heated to 80 ° C. and stirred, polyoxyethylene sulfosuccinate lauryl disodium, N-coconut oil fatty acid acylglycine sodium, lauraminopropionate sodium, 1,3-butylene glycol, phenoxyethanol, EDTA-2Na and citric acid are sequentially added and cooled to 50 ° C. with stirring until uniform. Further, the augone extract and dipotassium glycyrrhizinate are sequentially added while stirring, and the mixture is stirred until uniform.
下記に示す配合のトリートメントを調製した。
カチオン化加水分解コラーゲン 5.0重量%
ベヘントリモニウムクロリド 1.0重量%
ミリスチルジメチルアミンオキシド液 5.0重量%
ミリスチン酸イソプロピル 5.0重量%
ヒドロキシプロピルメチルセルロース 1.0重量%
乳酸モノエタノールアミド 3.0重量%
オウゴンエキス 0.5重量%
オウバクエキス 0.5重量%
グリチルリチン酸ジカリウム 0.3重量%
精製水 残部
A treatment having the composition shown below was prepared.
Cationized hydrolyzed collagen 5.0% by weight
Behentrimonium chloride 1.0% by weight
Myristyldimethylamine oxide solution 5.0% by weight
Isopropyl myristate 5.0% by weight
Hydroxypropyl methylcellulose 1.0% by weight
Lactic acid monoethanolamide 3.0% by weight
Ogon Extract 0.5% by weight
Oat extract 0.5% by weight
Dipotassium glycyrrhizinate 0.3% by weight
Purified water balance
調製方法としては、精製水に乳酸モノエタノールアミドを混合し、よく攪拌しながらヒドロキシプロピルメチルセルロースを80℃まで加温する。その後、カチオン化加水分解コラーゲン、ベヘントリモニウムクロリド、ミリスチルジメチルアミンオキシド液及びミリスチン酸イソプロピルを加える。次に、攪拌しながらオウゴンエキス、オウバクエキス、グリチルリチン酸ジカリウムを投入して均一になるまで攪拌して完成する。 As a preparation method, lactic acid monoethanolamide is mixed with purified water, and hydroxypropylmethylcellulose is heated to 80 ° C. with good stirring. Thereafter, cationized hydrolyzed collagen, behentrimonium chloride, myristyldimethylamine oxide solution and isopropyl myristate are added. Next, with stirring, ougon extract, buckwheat extract, and dipotassium glycyrrhizinate are added and stirred until uniform.
下記に示す配合のトリートメントを調製した。
ヒドロキシプロピルメチルセルロース 1.5重量%
ベヘントリモニウムクロリド 1.0重量%
アセチルモノエタノールアミド 3.0重量%
塩化ステアリルジメチルベンジルアンモニウム 1.0重量%
カチオン化加水分解シルク 2.0重量%
1,3−ブチレングリコール 1.0重量%
オウバクエキス 0.2重量%
グリチルリチン酸ジカリウム 0.6重量%
精製水 残部
A treatment having the composition shown below was prepared.
Hydroxypropyl methylcellulose 1.5% by weight
Behentrimonium chloride 1.0% by weight
Acetyl monoethanolamide 3.0% by weight
Stearyldimethylbenzylammonium chloride 1.0% by weight
Cationized hydrolyzed silk 2.0% by weight
1,3-butylene glycol 1.0% by weight
Oat extract 0.2% by weight
Dipotassium glycyrrhizinate 0.6% by weight
Purified water balance
調製方法としては、精製水の1/3量を85℃まで加熱し、この温水にヒドロキシプロピルメチルセルロースを分散させ、のこり2/3量の精製水を加え、水和物になるまで攪拌する。次にベヘントリモニウムクロリド、アセチルモノエタノールアミド及び塩化ステアリルジメチルベンジルアンモニウムを順次、添加後透明になるまで混合し、40℃まで冷却する。更に、カチオン化加水分解シルク及び1,3−ブチレングリコールを加えて透明になるまで攪拌した後、オウバクエキス、グリチルリチン酸ジカリウムを投入して均一になるまで攪拌して完成する。 As a preparation method, 1/3 amount of purified water is heated to 85 ° C., hydroxypropylmethylcellulose is dispersed in this warm water, 2/3 amount of purified water is added, and the mixture is stirred until it becomes a hydrate. Next, behentrimonium chloride, acetyl monoethanolamide and stearyldimethylbenzylammonium chloride are sequentially mixed after addition until it becomes transparent, and cooled to 40 ° C. Further, after adding cationized hydrolyzed silk and 1,3-butylene glycol and stirring until transparent, the agate extract and dipotassium glycyrrhizinate are added and stirred until uniform.
下記に示す配合のトリートメントを調製した。
塩化アルキルトリメチルアンモニウム 6.0重量%
アセチルモノエタノールアミド 1.0重量%
PEGアーモンドグリセライド 0.5重量%
ポリオキシエチレンステアリルエーテル 0.5重量%
セタノール 2.0重量%
ミネラルオイル 3.0重量%
ステアリルアルコール 2.0重量%
テトラステアリン酸ペンタエリスリトール 1.0重量%
トリエタノールアミン 0.06重量%
水解小麦胚芽プロテイン 2.0重量%
グリセリン 1.0重量%
オウゴンエキス 0.5重量%
オウバクエキス 0.5重量%
グリチルリチン酸ジカリウム 0.5重量%
精製水 残部
A treatment having the composition shown below was prepared.
Alkyltrimethylammonium chloride 6.0% by weight
Acetyl monoethanolamide 1.0% by weight
PEG almond glyceride 0.5% by weight
Polyoxyethylene stearyl ether 0.5% by weight
Cetanol 2.0% by weight
Mineral oil 3.0% by weight
Stearyl alcohol 2.0% by weight
Pentaerythritol tetrastearate 1.0% by weight
Triethanolamine 0.06% by weight
Hydrolyzed wheat germ protein 2.0% by weight
Glycerin 1.0% by weight
Ogon Extract 0.5% by weight
Oat extract 0.5% by weight
Dipotassium glycyrrhizinate 0.5% by weight
Purified water balance
調製方法としては、塩化アルキルトリメチルアンモニウム、アセチルモノエタノールアミド及び精製水を85℃まで加熱して混合する。PEGアーモンドグリセライド、ポリオキシエチレンステアリルエーテル、セタノール、ミネラルオイル、ステアリルアルコール及びテトラステアリン酸ペンタエリスリトールを85℃まで加熱して混合し、塩化アルキルトリメチルアンモニウム、アセチルモノエタノールアミド及び精製水の混合物に加え、45℃まで冷却する。攪拌を継続しながらトリエタノールアミンを加え、更に水解小麦胚芽プロテイン及びグリセリンを添加し、次いでオウゴンエキス、オウバクエキス、グリチルリチン酸ジカリウムを投入して均一になるまで攪拌して完成する。 As a preparation method, alkyl trimethyl ammonium chloride, acetyl monoethanolamide and purified water are heated to 85 ° C. and mixed. PEG almond glyceride, polyoxyethylene stearyl ether, cetanol, mineral oil, stearyl alcohol and pentaerythritol tetrastearate are heated to 85 ° C and mixed, added to the mixture of alkyltrimethylammonium chloride, acetyl monoethanolamide and purified water, Cool to 45 ° C. While continuing stirring, triethanolamine is added, hydrolyzed wheat germ protein and glycerin are added, and then gonon extract, buckwheat extract, and dipotassium glycyrrhizinate are added and stirred until uniform.
下記に示す配合のローションを調製した。
ヒドロキシエチルセルロース 0.5重量%
1,3−ブチレングリコール 2.0重量%
フェノキシエタノール 0.5重量%
アラントイン 0.1重量%
オウゴンエキス 2.0重量%
グリチルリチン酸ジカリウム 0.1重量%
精製水 残部
A lotion having the composition shown below was prepared.
Hydroxyethyl cellulose 0.5% by weight
1,3-butylene glycol 2.0% by weight
Phenoxyethanol 0.5% by weight
Allantoin 0.1% by weight
Ougon extract 2.0% by weight
Dipotassium glycyrrhizinate 0.1% by weight
Purified water balance
調製方法としては、ヒドロキシエチルセルロース、1,3−ブチレングリコール、フェノキシエタノール及び精製水を80℃に加熱し、均一になるまで攪拌しながら50℃まで冷却する。次にゆっくり攪拌しながらアラントイン、オウゴンエキス及びグリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, hydroxyethyl cellulose, 1,3-butylene glycol, phenoxyethanol and purified water are heated to 80 ° C. and cooled to 50 ° C. with stirring until uniform. Next, allantoin, ougon extract and dipotassium glycyrrhizinate are sequentially added while stirring slowly, and the mixture is stirred until uniform.
下記に示す配合のローションを調製した。
ソルビトール(70%) 5.0重量%
グリセリン 5.0重量%
フェノキシエタノール 0.5重量%
モノヤシ油脂肪酸POE(20)ソルビタン 0.5重量%
酢酸トコフェロール 0.1重量%
オウゴンエキス 0.5重量%
オウバクエキス 0.5重量%
グリチルリチン酸ジカリウム 1.0重量%
精製水 残部
A lotion having the composition shown below was prepared.
Sorbitol (70%) 5.0% by weight
Glycerin 5.0% by weight
Phenoxyethanol 0.5% by weight
Mono palm oil fatty acid POE (20) sorbitan 0.5% by weight
Tocopherol acetate 0.1% by weight
Ogon Extract 0.5% by weight
Oat extract 0.5% by weight
Dipotassium glycyrrhizinate 1.0% by weight
Purified water balance
調製方法としては、常温の精製水にソルビトール(70%)、グリセリン及びフェノキシエタノールを順次投入し攪拌する。次にモノヤシ油脂肪酸POE(20)ソルビタン及び酢酸トコフェロールをよく混合し分散させてから前記攪拌物に投入し攪拌する。更に、ゆっくり攪拌しながらオウゴンエキス、オウバクエキス及びグリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, sorbitol (70%), glycerin and phenoxyethanol are sequentially added and stirred in purified water at normal temperature. Next, the monococonut oil fatty acid POE (20) sorbitan and tocopherol acetate are mixed well and dispersed, and then charged into the agitated material and stirred. Further, with slow stirring, ougon extract, buckwheat extract and dipotassium glycyrrhizinate are sequentially added and stirred until uniform.
下記に示す配合のローションを調製した。
ミネラルオイル 3.0重量%
ラノリンアルコール 2.0重量%
セチルアルコール 2.0重量%
ステアリン酸グリセリル 3.0重量%
カチオン化ヒドロキシエチルセルロース 0.5重量%
グリセリン 3.0重量%
フェノキシエタノール 0.5重量%
オウゴンエキス 1.0重量%
オウバクエキス 1.0重量%
グリチルリチン酸ジカリウム 0.2重量%
精製水 残部
A lotion having the composition shown below was prepared.
Mineral oil 3.0% by weight
Lanolin alcohol 2.0% by weight
Cetyl alcohol 2.0% by weight
Glyceryl stearate 3.0% by weight
Cationized hydroxyethyl cellulose 0.5% by weight
Glycerin 3.0% by weight
Phenoxyethanol 0.5% by weight
Ogon Extract 1.0% by weight
Oat extract 1.0% by weight
Dipotassium glycyrrhizinate 0.2% by weight
Purified water balance
調製方法としては、ミネラルオイル、ラノリンアルコール、セチルアルコール及びステアリン酸グリセリルを80℃に加熱し、攪拌して油相Aを調製する。又、カチオン化ヒドロキシエチルセルロース及び精製水を冷却攪拌して分散させた後、グリセリン及びフェノキシエタノールを順次投入し80℃に加熱し攪拌して水相Bを調整する。次に、80℃の油相Aに水相Bを投入し、均一になるまで攪拌し、50℃まで冷却する。更に、ゆっくり攪拌しながらオウゴンエキス、オウバクエキス及びグリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, mineral oil, lanolin alcohol, cetyl alcohol and glyceryl stearate are heated to 80 ° C. and stirred to prepare oil phase A. In addition, after cationized hydroxyethyl cellulose and purified water are cooled and stirred to disperse, glycerin and phenoxyethanol are sequentially added, heated to 80 ° C. and stirred to adjust the aqueous phase B. Next, the water phase B is added to the oil phase A at 80 ° C., stirred until uniform, and cooled to 50 ° C. Further, with slow stirring, ougon extract, buckwheat extract and dipotassium glycyrrhizinate are sequentially added and stirred until uniform.
下記に示す配合のボディーソープを調製した。
ヒドロキシエタンジホスホン酸 0.2重量%
2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミタゾリニウムベタイン
16.0重量%
ラウロイルサルコシンナトリウム 14.2重量%
ヤシ油脂肪酸メチルアラニンナトリウム 8.56重量%
ヤシ油脂肪酸モノイソプロパノールアミド 2.1重量%
テトラステアリン酸ポリオキシエチレンベンタエリスリット 1.1重量%
オウゴンエキス 0.5重量%
オウバクエキス 0.5重量%
グリチルリチン酸ジカリウム 0.6重量%
精製水 残部
A body soap having the following composition was prepared.
Hydroxyethanediphosphonic acid 0.2% by weight
2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine
16.0% by weight
Lauroyl sarcosine sodium 14.2% by weight
Palm oil fatty acid sodium methylalanine 8.56% by weight
Palm oil fatty acid monoisopropanolamide 2.1 wt%
1.1% by weight of tetraoxystearate polyoxyethylene benterislit
Ogon Extract 0.5% by weight
Oat extract 0.5% by weight
Dipotassium glycyrrhizinate 0.6% by weight
Purified water balance
調製方法としては、ヒドロキシエタンジホスホン酸及び精製水を攪拌しながら80℃まで加熱し、調製剤Cを調製する。又、ヤシ油脂肪酸モノイソプロパノールアミド及びテトラステアリン酸ポリオキシエチレンベンタエリスリットも均一に攪拌しながら80℃まで加熱し、調製剤Dを調製する。調製剤Cが80℃になったら、2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミタゾリニウムベタイン、ラウロイルサルコシンナトリウム、ヤシ油脂肪酸メチルアラニンナトリウム及び調製剤Dを順次添加し均一に攪拌する。50℃まで冷却し、ゆっくり攪拌しながらオウゴンエキス、オウバクエキス及びグリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, hydroxyethane diphosphonic acid and purified water are heated to 80 ° C. with stirring to prepare Preparation C. Further, coconut oil fatty acid monoisopropanolamide and tetrastearic acid polyoxyethylene benterislit are also heated to 80 ° C. with uniform stirring to prepare Preparation D. When Preparation C reaches 80 ° C., add 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine, sodium lauroyl sarcosine, sodium palm oil fatty acid methylalanine and Preparation D in order and stir uniformly. To do. The mixture is cooled to 50 ° C., and slowly mixed with argon extract, buckwheat extract and dipotassium glycyrrhizinate and stirred until uniform.
下記に示す配合のボディーソープを調製した。
ラウロイルサルコシンナトリウム 40.0重量%
ラウリン酸アミドプロピルジメチルアミンオキシド液 17.0重量%
ポリオキシプロピレン(1)ヤシ油脂肪酸モノイソプロパノールアミド 3.0重量%
トリイソステアリン酸ポリオキシエチレンソルビタン 1.5重量%
ミリスチン酸 1.0重量%
ミリスチルアルコール 0.3重量%
プロピレングリコール 2.0重量%
ジステアリン酸エチレングリコール 2.0重量%
フェノキシエタノール 0.5重量%
L−グルタミン酸 0.2重量%
オウバクエキス 1.0重量%
グリチルリチン酸ジカリウム 0.2重量%
精製水 残部
A body soap having the following composition was prepared.
Lauroyl sarcosine sodium 40.0% by weight
Lauric acid amidopropyldimethylamine oxide solution 17.0% by weight
Polyoxypropylene (1) Palm oil fatty acid monoisopropanolamide 3.0% by weight
1.5% by weight of polyoxyethylene sorbitan triisostearate
Myristic acid 1.0% by weight
Myristyl alcohol 0.3% by weight
Propylene glycol 2.0% by weight
2.0% by weight ethylene glycol distearate
Phenoxyethanol 0.5% by weight
L-glutamic acid 0.2% by weight
Oat extract 1.0% by weight
Dipotassium glycyrrhizinate 0.2% by weight
Purified water balance
調製方法としては、精製水とフェノキシエタノールを攪拌しながら80℃まで加熱し、調製剤Eを調製する。又、ポリオキシプロピレン(1)ヤシ油脂肪酸モノイソプロパノールアミド、トリイソステアリン酸ポリオキシエチレンソルビタン、ミリスチン酸、ミリスチルアルコール、プロピレングリコール及びジステアリン酸エチレングリコールを攪拌しながら80℃まで加熱し、調製剤Fを調整する。80℃に加熱された調製剤Eにラウロイルサルコシンナトリウム及びラウリン酸アミドプロピルジメチルアミンオキシド液を攪拌しながら順次投入し、その後調製剤Fを加え均一に攪拌する。50℃まで冷却し、ゆっくり攪拌しながらL−グルタミン酸、オウバクエキス及びグリチルリチン酸ジカリウムを順次投入して均一になるまで攪拌して完成する。 As a preparation method, purified water and phenoxyethanol are heated to 80 ° C. with stirring to prepare Preparation E. In addition, polyoxypropylene (1) coconut oil fatty acid monoisopropanolamide, polyisoethylene stearic acid polyoxyethylene sorbitan, myristic acid, myristyl alcohol, propylene glycol and ethylene glycol distearate are heated to 80 ° C. with stirring, adjust. To the preparation E heated to 80 ° C., sodium lauroyl sarcosine and amidopropyldimethylamine oxide laurate solution are sequentially added while stirring, and then the preparation F is added and stirred uniformly. It cools to 50 degreeC, L-glutamic acid, an agate extract, and dipotassium glycyrrhizinate are thrown in in order, stirring slowly until it becomes uniform.
下記に示す配合のボディーソープを調製した。
ポリオキシエチレンラウリルエーテル硫酸ナトリウム 22.2重量%
ラウリン酸アミドプロピルジメチルアミンオキシド液 20.0重量%
N−ヤシ油脂肪酸アシル−L−グルタミン酸カリウム 7.0重量%
ポリオキシプロピレン(1)ヤシ油脂肪酸モノイソプロパノールアミド 3.0重量%
フェノキシエタノール 0.3重量%
オウゴンエキス 0.3重量%
グリチルリチン酸ジカリウム 0.8重量%
L−グルタミン酸 0.2重量%
精製水 残部
A body soap having the following composition was prepared.
Sodium polyoxyethylene lauryl ether sulfate 22.2% by weight
Lauric acid amidopropyldimethylamine oxide solution 20.0% by weight
N-coconut oil fatty acid acyl-potassium L-glutamate 7.0% by weight
Polyoxypropylene (1) Palm oil fatty acid monoisopropanolamide 3.0% by weight
Phenoxyethanol 0.3% by weight
Ogon Extract 0.3% by weight
Dipotassium glycyrrhizinate 0.8% by weight
L-glutamic acid 0.2% by weight
Purified water balance
調製方法としては、フェノキシエタノール及び精製水を攪拌しながら80℃まで加熱し、調製剤Gを調整する。N−ヤシ油脂肪酸アシル−L−グルタミン酸カリウム及びポリオキシプロピレン(1)ヤシ油脂肪酸モノイソプロパノールアミドを攪拌しながら80℃まで加熱し、調製剤Hを調整する。80℃の調製剤Gにポリオキシエチレンラウリルエーテル硫酸ナトリウム及びラウリン酸アミドプロピルジメチルアミンオキシド液を攪拌しながら加え、更に、調製剤Hを加えて攪拌し、均一化し、50℃まで冷却し、オウゴンエキス、グリチルリチン酸ジカリウム及びL−グルタミン酸を順次投入して均一になるまで攪拌して完成する。 As a preparation method, phenoxyethanol and purified water are heated to 80 ° C. with stirring to prepare Preparation G. N-coconut oil fatty acid acyl-potassium L-glutamate and polyoxypropylene (1) Coconut oil fatty acid monoisopropanolamide is heated to 80 ° C. with stirring to prepare Preparation H. Polyoxyethylene lauryl ether sodium sulfate and amidopropyl dimethylamine oxide liquid were added to 80 ° C. preparation G while stirring, and further, preparation H was added and stirred, homogenized, cooled to 50 ° C., The extract, dipotassium glycyrrhizinate and L-glutamic acid are added sequentially and stirred until uniform to complete.
下記に示す配合のボディーソープを調製した。
ラウリン酸 9.0重量%
ミリスチン酸 4.5重量%
水酸化カリウム 4.0重量%
ラウリルジメチルアミンオキシド 8.0重量%
ヤシ油脂肪酸アミドプロピルベタイン 8.0重量%
ステアリン酸ジエタノールアミド 3.0重量%
ジステアリン酸グリコール 2.0重量%
ベタイン 1.5重量%
フェノキシエタノール 0.5重量%
オウゴンエキス 0.3重量%
オウバクエキス 0.3重量%
精製水 残部
A body soap having the following composition was prepared.
Lauric acid 9.0% by weight
Myristic acid 4.5% by weight
Potassium hydroxide 4.0% by weight
Lauryldimethylamine oxide 8.0% by weight
Palm oil fatty acid amidopropyl betaine 8.0% by weight
Stearic acid diethanolamide 3.0% by weight
Glycol distearate 2.0% by weight
Betaine 1.5% by weight
Phenoxyethanol 0.5% by weight
Ogon Extract 0.3% by weight
Oat extract 0.3% by weight
Purified water balance
調製方法としては、精製水に水酸化カリウムを溶解させ、攪拌しながらラウリン酸及びミリスチン酸を加え60℃まで加熱する。次いでラウリルジメチルアミンオキシド及びヤシ油脂肪酸アミドプロピルベタインを投入し攪拌し、調製剤Iを調製する。又、別釜でステアリン酸ジエタノールアミド及びジステアリン酸グリコールを完全に溶解するまで加熱、攪拌して調製剤Iに投入し、更にベタイン及びフェノキシエタノールを順次投入攪拌し、均一化して50℃まで冷却する。その後オウゴンエキス及びオウバクエキスを順次投入して均一になるまで攪拌して完成する。 As a preparation method, potassium hydroxide is dissolved in purified water, lauric acid and myristic acid are added with stirring, and the mixture is heated to 60 ° C. Next, lauryl dimethylamine oxide and coconut oil fatty acid amidopropyl betaine are added and stirred to prepare Preparation I. Further, in a separate kettle, stearic acid diethanolamide and glycol distearate are heated and stirred until they are completely dissolved, and then added to Preparation I, and betaine and phenoxyethanol are sequentially added and stirred, homogenized and cooled to 50 ° C. After that, the Ogon extract and the Oat extract are sequentially added and stirred until they are uniform.
下記に示す配合のヘアセット剤を調製した。
酢酸リナリル変性アルコール 3.0重量%
酢酸ビニル・ビニルピロリドン共重合体 2.0重量%
ヒアルロン酸ナトリウム 0.001重量%
アミノエチル・アミノプロピルシロキサンジメチルシロキサン共重合体エマルジョン
1.0重量%
オウゴンエキス 2.0重量%
オウバクエキス 2.0重量%
グリチルリチン酸ジカリウム 2.0重量%
精製水 残部
A hair set agent having the composition shown below was prepared.
Linalyl acetate modified alcohol 3.0% by weight
Vinyl acetate / vinyl pyrrolidone copolymer 2.0% by weight
Sodium hyaluronate 0.001% by weight
Aminoethyl-aminopropylsiloxane dimethylsiloxane copolymer emulsion
1.0% by weight
Ougon extract 2.0% by weight
Oat extract 2.0% by weight
Dipotassium glycyrrhizinate 2.0% by weight
Purified water balance
調製方法としては、酢酸ビニル・ビニルピロリドン共重合体及び精製水を混合攪拌して均一とした後に、他の成分を順次ゆっくりと加えて均一になるまで攪拌して完成する。 As a preparation method, a vinyl acetate / vinyl pyrrolidone copolymer and purified water are mixed and stirred to be uniform, and then other components are slowly added in order and stirred until uniform.
下記に示す配合のヘアセット剤を調製した。
酢酸リナリル変性アルコール 83.3重量%
酢酸ビニル・ビニルピロリドン共重合体 10.0重量%
ポリビニルピロリドン 3.0重量%
ヒドロキシプロピルキトサン 1.5重量%
オウゴンエキス 1.0重量%
オウバクエキス 1.0重量%
グリチルリチン酸ジカリウム 0.2重量%
A hair set agent having the composition shown below was prepared.
Linalyl acetate-modified alcohol 83.3% by weight
Vinyl acetate / vinyl pyrrolidone copolymer 10.0% by weight
Polyvinylpyrrolidone 3.0% by weight
Hydroxypropyl chitosan 1.5% by weight
Ogon Extract 1.0% by weight
Oat extract 1.0% by weight
Dipotassium glycyrrhizinate 0.2% by weight
調製方法としては、酢酸リナリル変性アルコール、酢酸ビニル・ビニルピロリドン共重合体及びポリビニルピロリドンを混合攪拌して均一とした後に、他の成分を順次ゆっくりと加えて均一になるまで攪拌して完成する。 As a preparation method, linalyl acetate-modified alcohol, vinyl acetate / vinyl pyrrolidone copolymer and polyvinyl pyrrolidone are mixed and stirred to be uniform, and then other components are slowly added in order and stirred until uniform.
下記に示す配合の二浴式コールドウェーブ用第1剤を調製した。
チオグリコール酸アンモニウム 10.0重量%
モノエタノールアミン 1.0重量%
アンモニア水 1.0重量%
ミンクオイル 0.3重量%
流動パラフィン 0.5重量%
ポリオキシエチレンオレイルエーテル(20E.O.) 0.2重量%
ポリオキシエチレンオレイルエーテル(4E.O.) 0.02重量%
香料 0.1重量%
グリセリン 0.5重量%
オウゴンエキス 0.8重量%
オウバクエキス 0.8重量%
グリチルリチン酸ジカリウム 0.3重量%
精製水 残部
The 1st agent for two bath type cold waves of the composition shown below was prepared.
Ammonium thioglycolate 10.0% by weight
Monoethanolamine 1.0% by weight
Ammonia water 1.0% by weight
Mink oil 0.3% by weight
Liquid paraffin 0.5% by weight
Polyoxyethylene oleyl ether (20E.O.) 0.2% by weight
Polyoxyethylene oleyl ether (4EO) 0.02% by weight
Fragrance 0.1% by weight
Glycerin 0.5% by weight
Ogon Extract 0.8% by weight
Oat extract 0.8% by weight
Dipotassium glycyrrhizinate 0.3% by weight
Purified water balance
調製方法としては、精製水にグリセリン以外の組成物を順次加えて均一に攪拌し、最後にグリセリンを加え均一に攪拌して調製する。 As a preparation method, a composition other than glycerin is sequentially added to purified water and stirred uniformly, and finally glycerin is added and stirred uniformly.
下記に示す配合の二浴式コールドウェーブ用第2剤を調製した。
臭素酸ナトリウム 7.0重量%
ポリオキシエチレンラノリン 0.01重量%
塩化セチルトリメチルアンモニウム 0.2重量%
エデト酸ニナトリウム 0.003重量%
塩化ジポリオキシエチレンオレイルメチルアンモニウム 0.4重量%
フェノキシエタノール 0.1重量%
ポリオキシノニルフェニルエーテル 0.7重量%
プロピレングリコール 0.3重量%
オウゴンエキス 1.0重量%
オウバクエキス 1.0重量%
グリチルリチン酸ジカリウム 0.5重量%
香料 1.0重量%
精製水 残部
The 2nd agent for two bath type cold waves of the composition shown below was prepared.
Sodium bromate 7.0% by weight
Polyoxyethylene lanolin 0.01% by weight
Cetyltrimethylammonium chloride 0.2% by weight
Edetate disodium 0.003% by weight
Dipolyoxyethylene oleylmethylammonium chloride 0.4% by weight
Phenoxyethanol 0.1% by weight
Polyoxynonyl phenyl ether 0.7% by weight
Propylene glycol 0.3% by weight
Ogon Extract 1.0% by weight
Oat extract 1.0% by weight
Dipotassium glycyrrhizinate 0.5% by weight
Fragrance 1.0% by weight
Purified water balance
調製方法としては、精製水に組成物を順次加えて均一に攪拌して調製する。 As a preparation method, the composition is sequentially added to purified water and uniformly stirred.
1 本発明のシャンプーを用いたへアレスマウスの写真
2 市販のシャンプーAを用いたへアレスマウスの写真
3 市販のシャンプーBを用いたへアレスマウスの写真
4 市販のシャンプーCを用いたへアレスマウスの写真
1 Photo of hairless mouse using shampoo of the present invention 2 Photo of hairless mouse using commercially
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005147031A JP2006321758A (en) | 2005-05-19 | 2005-05-19 | Cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005147031A JP2006321758A (en) | 2005-05-19 | 2005-05-19 | Cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2006321758A true JP2006321758A (en) | 2006-11-30 |
Family
ID=37541688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005147031A Pending JP2006321758A (en) | 2005-05-19 | 2005-05-19 | Cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006321758A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011514375A (en) * | 2008-03-17 | 2011-05-06 | ギウリアニ ソシエタ ペル アチオニ | Use of one or more glycyrrhizinates to reduce the stimulating action of surfactants in cosmetic compositions |
| JP2011190221A (en) * | 2010-03-16 | 2011-09-29 | Milbon Co Ltd | Hair treatment agent |
| JP2012514634A (en) * | 2009-01-09 | 2012-06-28 | ソウル大学校産学協力団 | Composition for improving inflammatory disease using ABH antigen |
| KR101463842B1 (en) | 2008-06-25 | 2014-11-26 | (주)아모레퍼시픽 | Skin external composition for recovering inflammation or hurt containing extracts of herbal medicine |
| JP2015061829A (en) * | 2013-08-23 | 2015-04-02 | 第一三共ヘルスケア株式会社 | Loxoprofen-containing external preparation composition |
| JP2016216402A (en) * | 2015-05-22 | 2016-12-22 | 花王株式会社 | Skin cosmetics |
-
2005
- 2005-05-19 JP JP2005147031A patent/JP2006321758A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011514375A (en) * | 2008-03-17 | 2011-05-06 | ギウリアニ ソシエタ ペル アチオニ | Use of one or more glycyrrhizinates to reduce the stimulating action of surfactants in cosmetic compositions |
| KR101463842B1 (en) | 2008-06-25 | 2014-11-26 | (주)아모레퍼시픽 | Skin external composition for recovering inflammation or hurt containing extracts of herbal medicine |
| JP2012514634A (en) * | 2009-01-09 | 2012-06-28 | ソウル大学校産学協力団 | Composition for improving inflammatory disease using ABH antigen |
| US8545851B2 (en) | 2009-01-09 | 2013-10-01 | Snu R&Db Foundation | Composition for improving inflammatory disease using ABH antigens |
| JP2011190221A (en) * | 2010-03-16 | 2011-09-29 | Milbon Co Ltd | Hair treatment agent |
| JP2015061829A (en) * | 2013-08-23 | 2015-04-02 | 第一三共ヘルスケア株式会社 | Loxoprofen-containing external preparation composition |
| JP2016216402A (en) * | 2015-05-22 | 2016-12-22 | 花王株式会社 | Skin cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100404019C (en) | Multivesicular emulsion topical delivery system | |
| CN102342993B (en) | Anti-sensitization and restoration external preparation for skin | |
| JP4955382B2 (en) | Epidermal release composition with anti-allergic and anti-inflammatory effects | |
| TW200526259A (en) | Methods for treating skin conditions | |
| JPS62292710A (en) | Skin cosmetic | |
| JP5765744B2 (en) | Preventive or therapeutic agent for atopic dermatitis, and external preparation | |
| US10420962B2 (en) | Organic hair formulation and treatment | |
| JP2006321758A (en) | Cosmetic | |
| JPS63115807A (en) | Cosmetic | |
| JPH05255044A (en) | Hair grower | |
| JPH10194947A (en) | Cosmetic composition containing extract of plant of family cannabaceae | |
| EP1192940A1 (en) | Compositions and methods for promoting clear skin using an alkanolamine | |
| JP3319870B2 (en) | Skin external composition and bath agent | |
| JPH07277920A (en) | Cosmetic containing steam-distilled water and/or extract of lemongrass | |
| RU2170570C1 (en) | Composition for hair washing | |
| JPH05286835A (en) | Hair-raising cosmetic | |
| JPH04124138A (en) | External preparation for skin | |
| Sang et al. | A Review on Synthetic Shampoo Ingredients and Their Adverse Health Effects | |
| JP3974003B2 (en) | Hair growth material and external preparation for skin containing the same | |
| JPH069363A (en) | Medicinal cosmetic | |
| KR0154648B1 (en) | Hair growth and restoration promoter | |
| JPH01135711A (en) | Hair tonic | |
| JP2004238297A (en) | Cosmetic for anti-skin stress (stress protection) | |
| JP7222483B2 (en) | Method for preparing cycad extract | |
| KR20200059659A (en) | Natural scalp powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090728 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100309 |